NCT05197179View on ClinicalTrials.gov

A Bridging Study of FB2001 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

April 27, 2022

Study Completion Date

June 2, 2022

Conditions
COVID-19
Interventions
DRUG

FB2001

Subjects will be administered with FB2001 by intravenous (IV) infusion

OTHER

FB2001 placebo

Subjects will be administered with FB2001 by intravenous (IV) infusion

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Frontier Biotechnologies Inc.

INDUSTRY